PILA PHARMA AB — Investor Relations & Filings

PILA PHARMA AB is a clinical-stage biotechnology company focused on developing treatments for metabolic diseases. The company is pioneering the development of XEN-D0501, a potential first-in-class, oral TRPV1 antagonist. This drug candidate is being investigated for the treatment of type 2 diabetes and, more recently, obesity. The company's approach aims to provide a novel, oral therapeutic alternative to address the growing global prevalence of these conditions by targeting the TRPV1 mechanism, also known as the 'chili-receptor'.